New CAR T-cell therapy for solid tumors was safe and showed early efficacy

A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

source https://medicalxpress.com/news/2022-04-car-t-cell-therapy-solid-tumors.html